Identifying the genomic alterations in non-small cell lung cancer (NSCLC) can allow healthcare professionals to make the most suitable treatment decisions for patients. A common mutation associated with NSCLC involves mesenchymal-epithelial transition (MET). Understanding the MET mutation, and other genomic mutations associated with NSCLC, can help develop more effective personalised treatment.
EMJ Oncology 10 [Supplement 5] . 2022
March 2022
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/04/Onc-Aparna-Parikh-Interview-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/03/TN-1-1-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/02/Eugena-Stamuli-thumbnail-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/02/GSK-ONC-010-23-2-Thumbnail-940x564.png)